January 27, 2021 – FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment secured, the Toronto-based company looks to bring innovative cancer therapies to Canadian patients, new treatment tools for caregivers and physicians, and … Continue reading New Canadian Pharmaceutical Company Brings Novel Cancer Therapies To Market →

January 25, 2021 – The global effort to develop and distribute COVID-19 vaccinations and therapeutics offer fresh hope after a difficult year. As we reflect, it’s a good time to recognize the impact that B.C.’s life-sciences sector is having here at home and around the world, and its place in planning for our province’s economic … Continue reading Wendy Hurlburt and Greg D’Avignon: B.C.’s critical role in building a healthy recovery →

January 25, 2021 – VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price … Continue reading Kardium announces $115M in new financing for innovative atrial fibrillation treatment →

January 25, 2021 – VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the … Continue reading FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis →

January 21, 2021 – You are invited to an update webinar on the amendments to the PMPRB Guidelines on Friday, January 29, from 12:00 noon to 1:00 p.m. (EST).   Mr. Steven Sampson, Senior Vice President, Health and Life Sciences, Global Public Affairs, will provide an update on the amendments to the PMPRB Guidelines resulting … Continue reading Innovative Medicines Canada PMPRB Guidelines Webinar for Stakeholders →

January 21, 2021 – The 2020 Innovation to Commercialization and Health Professional-Investigator awardees are advancing health research towards practical applications, improving patient care, and developing made-in-BC technologies. We are British Columbia’s health research funding agency. Our programs are designed to develop, retain, and attract the people whose research improves the health of British Columbians, addresses … Continue reading MSFHR funds 19 innovators to advance made-in-BC health research and discoveries for improved patient care →

Vancouver, BC – January 19, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe … Continue reading InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe →

January 18, 2021 – Innovative Solutions Canada has posted an Open Call today for innovative prototypes, which includes a Health stream under the standard component. The Testing Stream aims to procure, test and evaluate innovative late stage pre-commercial prototypes. The purpose of these calls for proposals (CFPs) is to create pools of pre-qualified innovations that Canada may … Continue reading Testing Stream — Open calls for innovative prototypes →

VANCOUVER, BC, Jan. 18, 2021 /CNW/ – ImmunoFlex™, a life sciences company developing clinically validated, pharmaceutical grade natural health products based on advancements in genomics research, today announced the approval of FLEX 10™ by Health Canada. “At ImmunoFlex, we work with the immune system to strengthen, support, and enhance our body’s natural surveillance and response system.” said … Continue reading ImmunoFlex™ Receives FLEX 10™ Product Approval From Health Canada →

January 15, 2021 – Applications are live for our entrepreneurship@UBC CORE and Lab2Launch Venture Building Program! Applications are due February 25th. CORE is for ventures driving innovation through disruptive trends and technologies (think AI, consumer goods, retail, agritech, software, hardware etc) and Lab2Launch is for researchers looking to get their innovations from lab to market. We … Continue reading entrepreneurship@UBC’s CORE and L2L Recruitment + Hiring in the US event coming up! →